Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ESKAPE
2024-518733-29-00Phase 4Completed
- Sponsor
- Centre Hospitalier Universitaire de Nice
- Start
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial comparing Esketamine low-dose with Ketamine low-dose (2 arms). Primary endpoint: Proportion of patients experiencing at least one psychodysleptic effect. Started Mar 2025; status: completed.
02
Drugs
esketamineketamine
Beyond the preview
Go deeper on 2024-518733-29-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518733-29-00.